
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company advancing cell therapies for autoimmune diseases. Guided by our core values—Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome—we are building the foundation for the next generation of cell therapy. This is an opportunity to join at a critical stage and directly shape how clinical development is executed as we scale.
Kyverna is seeking a Senior Clinical Research Scientist who thrives in a fast-paced, build-phase environment and is motivated by the opportunity to create, implement, and optimize clinical processes from the ground up. This role will support the design, execution, and analysis of clinical studies in accordance with GCP and regulatory requirements.
This individual will operate with a high degree of ownership and autonomy, partnering cross-functionally with Clinical Operations, Medical, Biometrics, Regulatory, and external partners to drive high-quality study execution. The ideal candidate is a proactive, hands-on, team player with strong analytical skills.
Department: Clinical Development
Location: Remote eligible
Reports To: Director, Clinical Research Scientist
The national salary range for this position is $140,000 to $160,000 USD annually. Actual compensation may vary based on experience, skills, and internal equity. This role is also eligible for bonus, benefits, and equity participation.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.